{'fraction_non_alphanumeric': 0.021839080459770115, 'fraction_numerical': 0.013793103448275862, 'mean_word_length': 4.885135135135135, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The future of blood pressure control in a population with a growing girth.

In spite of the more than 125 different antihypertensive medications already available for the treatment of hypertension, control rates among those with chronic kidney disease (CKD) remain well below that of the general population. Less than 30% of those with CKD have their blood pressure (BP) controlled to the recommended guideline goal of less than 130/80 mmHg [1–3]. In spite of this cornucopia of medications newer agents within older classes and new classes have been developed. An example of a new class of agents is the renin inhibitors for BP lowering. These agents have some unique pharmacologic characteristics and have a safety profile similar to angiotensin receptor blockers (ARBs). What their place is in the armamentarium of overall BP control is unclear but will be discussed.